![Patrik Strömberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Patrik Strömberg
Vorstandsvorsitzender bei AnaCardio AB
Aktive Positionen von Patrik Strömberg
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AnaCardio AB
![]() AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Vorstandsvorsitzender | 01.09.2021 | - |
Strike Pharma AB
![]() Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | Direktor/Vorstandsmitglied | 01.05.2021 | - |
Karriereverlauf von Patrik Strömberg
Statistik
International
Schweden | 3 |
Operativ
Chief Executive Officer | 1 |
Director/Board Member | 1 |
Sektoral
Health Technology | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
AnaCardio AB
![]() AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |
Strike Pharma AB
![]() Strike Pharma AB Miscellaneous Commercial ServicesCommercial Services Strike Pharma AB is a Swedish company that specializes in developing therapeutic vaccines for solid tumors. The company is based in Uppsala, Sweden and was founded in 2020 by Pierre Dönnes and Sara Mangsbo. The company utilizes ADAC technology to create personalized immunotherapy for their patients. Mårten Winge has been the CEO of the company since 2021. | Commercial Services |
- Börse
- Insiders
- Patrik Strömberg
- Erfahrung